Drug development for exceptionally rare metabolic diseases: challenging but not impossible.
BACKGROUND
We studied to what extent the level of scientific knowledge on exceptionally rare metabolic inherited diseases and their potential orphan medicinal products is associated with sponsors deciding to apply for an orphan designation at the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA).


METHODS
All metabolic diseases with a genetic cause and prevalence of less than 10 patients per 1 million of the population were selected from the 'Orphanet database of Rare diseases'. The outcome of interest was the application for an orphan designation at FDA or EMA. The level of publicly available knowledge of the disease and drug candidate before an orphan designation application was defined as whether the physiological function corresponding with the pathologic gene and initiation of the pathophysiological pathway was known, whether an appropriate animal study was identified for the disease, whether preclinical proof of concept was ascertained and the availability of data in humans. Other determinants included in the study were metabolic disease class, the prevalence of the disease, prognosis and time of first description of the disease in the literature. Univariate relative risks (RRs) and 95% confidence intervals (CIs) of an orphan designation application were calculated for each of these determinants. In addition, a multivariate Cox regression analysis was conducted (Forward LR).


RESULTS
In total, 166 rare metabolic genetic diseases were identified and included in the analysis. For only 42 (25%) of the diseases an orphan designation application was submitted at either FDA or EMA before January 2012. The multivariate analysis identified preclinical proof of concept of a potential medicinal product as major knowledge related determinant associated with an orphan designation application (RRadj 3.9, 95% CI 1.9-8.3) and confirmed that prevalence of the disease is also associated with filing an application for an orphan designation (RRadj 2.8, 95% CI 1.4-5.4).


CONCLUSIONS
For only one out of four known exceptionally rare metabolic inherited diseases sponsors applied for an orphan designation at FDA or EMA. These applications were found to be associated with the prevalence of the rare disease and the level of available scientific knowledge on the proof of concept linking possible drug candidates to the disease of interest.
Michelle
M
Putzeist
Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, P,O, Box 80 082, 3508TB Utrecht, The Netherlands. a.k.mantel@uu.nl.
Aukje K
AK
Mantel-Teeuwisse
Christine C Gispen-de
CC
Wied
Arno W
AW
Hoes
Hubert G M
HG
Leufkens
Remco L A
RL
de Vrueh
D017277:Drug Approval; D005060:Europe; D005260:Female; D006801:Humans; D008297:Male; D008659:Metabolic Diseases; D009965:Orphan Drug Production / Q000331:legislation & jurisprudence; D035583:Rare Diseases / Q000188:drug therapy* / Q000453:epidemiology; D014481:United States; D014486:United States Food and Drug Administration